Home DNA Damage/DNA Repair DNA/RNA Synthesis inhibitor Nedaplatin

research use only

Nedaplatin DNA/RNA Synthesis inhibitor

Cat.No.S1826

Nedaplatin(NSC 375101D) is a derivative of cisplatin and DNA damage agent for tumor colony forming units with IC50 of 94 μM.DMSO is not recommended to dissolve platinum-based drugs, which can easily lead to drug inactivation.
Nedaplatin DNA/RNA Synthesis inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 303.17

Jump to

Quality Control

Batch: Purity: 99.74%
99.74

Solubility

In vitro
Batch:

Water : 30 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 303.17 Formula

C2H8N2O3Pt

 Storage (From the date of receipt) 2 years 4°C(in the dark) powder
CAS No. 95734-82-0 -- Storage of Stock Solutions Solutions are unstable. Prepare fresh or purchase small, pre-packaged sizes. Repackage upon receipt.
Synonyms NSC 375101D SMILES C(C(=O)O)O.N.N.[Pt]

Read more about storage stability CAS number SMILES

Mechanism of Action

Features
This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).
Targets/IC50/Ki
DNA synthesis
In vitro

Nedaplatin (Aqupla) is a derivative of cisplatin for inhibition of tumor colony forming units with IC50 of 28.5 μg/mL. This compound is a platinum compound which is used for cancer chemotherapy. It inhibits the proliferation of SBC-3 cells by 98%, 93%, 75%, 54%, 27%, 6%, and 2% at a concentration of 0.005 μg/mL, 0.01 μg/mL, 0.025 μg/mL, 0.05 μg/mL, 0.1 μg/mL, 0.25 μg/mL, and 0.5 μg/mL, respectively. The IC50 value of this chemical for growth inhibition of SBC-3 cells is 0.053 μg/mL.

In vivo

The sequential administration of 5-FU prior to nedaplatin or CDDP (FN or FC therapy) results in synergistically enhanced inhibition of tumour growth and prolonged survival in comparison with this compound, CDDP or 5-FU monotherapy. Combined dosing of this compound with gemcitabine results in synergistically enhanced inhibition of tumor growth in the Ma44 tumor model. This chemical plus Gemcitabine is also effective against Ma44 cells when given late in the therapy, a model for advanced disease. Potent augmentation of growth inhibition by this compound with Gemcitabine is also found with the NCI-H460 tumor model.

References
  • [4] https://pubmed.ncbi.nlm.nih.gov/9893671/
  • [5] https://pubmed.ncbi.nlm.nih.gov/11173544/
  • [6] https://pubmed.ncbi.nlm.nih.gov/24812268/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-03-27)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06953323 RECRUITING
Advanced Solid Tumor
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
 2025-07-10 PHASE1; PHASE2
NCT07374003 ACTIVE_NOT_RECRUITING
Locally Advanced, Resectable
Sun Yat-sen University
 2025-12-17 PHASE2
NCT04437329 RECRUITING
Nasopharyngeal Carcinoma
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
 2020-08-01 PHASE3
NCT07284836 RECRUITING
Hepatic Artery Infusion; Liver Metastasis of Breast Cancer
Zhejiang Cancer Hospital
 2025-02-01 PHASE2
NCT07046221 NOT_YET_RECRUITING
Esophagus Cancer
Fujian Cancer Hospital
 2025-08-01 PHASE2
NCT06508229 NOT_YET_RECRUITING
Esophageal Squamous Cell Carcinoma
Harbin Medical University
 2024-07-30 PHASE2

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map